Saturday, October 25, 2014 Last update: 5:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting

Companies mentioned in this article: Plexxikon

BERKELEY, Calif. -- (BUSINESS WIRE) -- Plexxikon, a member of the Daiichi Sankyo Group, announced today that data related to PLX3397, a novel oral small molecule that potently and selectively inhibits CSF1R, KIT and mutant FLT3 kinases, will be presented in three separate presentations at the 50th American Society of Clinical Oncology (ASCO) 2014 Annual Meeting taking place May 30-June 3, 2014, in Chicago, Illinois.

Earlier today, Plexxikon’s Phase I study with PLX3397 in pigmented villonodular synovitis (PVNS), was featured as part of the highly selective ASCO Press Program. More detailed data will be shared in an oral presentation during the meeting (see below for details).

Oral Presentations

Abstract #10503: “A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS),” presented by William D. Tap, MD, principal investigator and Chief of the Sarcoma Medical Oncology Service, at Memorial Sloan Kettering Cancer Center (MSKCC), on Sunday, June 1 at 9:00 AM in Room S406.

Poster Presentations

Abstract #2023: “A Phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma,” on Friday, May 30 at 1:00 PM - 4:00 PM in E354b.

Abstract #TPS3127: “A Phase 1B study to assess the safety of PLX3397 and paclitaxel in patients with advanced solid tumors,” on Sunday, June 1 at 8:00 AM - 11:45 AM in S Hall A2.

About PLX3397

PLX3397 is a novel oral small molecule that potently and selectively inhibits CSF1R, KIT, and mutant FLT3 kinases. CSF1R and KIT regulate key components of both the tumor and its microenvironment (macrophages, osteoclasts, mast cells). In addition to PVNS, PLX3397 is being evaluated in several other clinical indications, including glioblastoma, melanoma, acute myelogenous leukemia and breast cancer. For more information on PLX3397 clinical trials, please visit clinicaltrials.gov.

About Plexxikon

Plexxikon, a member of the Daiichi Sankyo Group since April 2011, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s drug Zelboraf®, (vemurafenib/PLX4032) was approved by the FDA in 2011, and is being co-promoted in the U.S. by Daiichi Sankyo Inc. and Genentech. Plexxikon is developing a portfolio of preclinical and clinical stage compounds to address significant unmet medical needs in oncology and other therapeutic areas. Plexxikon’s Scaffold-Based Drug DiscoveryTM platform integrates multiple state-of-the-art technologies, including structural screening as a key component that provides a significant advantage over other drug discovery approaches.


Copyright © Business Wire 2014
Contact:

Plexxikon Inc.
Paul Lin, MD, MBA, +1 510-647-4063
COO
plin@plexxikon.com
or
For Plexxikon
Susan Kinkead, +1 415-751-3611
susan@kinkeadcomm.com